Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes

Burgess, M., Ellis, J. J., Mapp, S., Mollee, P., Mazzieri, R., Mattarollo, S. R., Gill, D. and Saunders, N. A. (2016) Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes. Genomics Data, 7 4-6. doi:10.1016/j.gdata.2015.11.010


Author Burgess, M.
Ellis, J. J.
Mapp, S.
Mollee, P.
Mazzieri, R.
Mattarollo, S. R.
Gill, D.
Saunders, N. A.
Title Transcriptomic analysis of monocytes and macrophages derived from CLL patients which display differing abilities to respond to therapeutic antibody immune complexes
Journal name Genomics Data   Check publisher's open access policy
ISSN 2213-5960
Publication date 2016-03-01
Year available 2015
Sub-type Article (original research)
DOI 10.1016/j.gdata.2015.11.010
Open Access Status DOI
Volume 7
Start page 4
End page 6
Total pages 3
Place of publication Amsterdam, Netherlands
Publisher Elsevier
Collection year 2016
Subject 1313 Molecular Medicine
1303 Specialist Studies in Education
1305 Biotechnology
1311 Genetics
Abstract Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. While therapeutic antibodies show clinical activity in CLL patients, resistance inevitably develops resulting in treatment failure. Identifying mechanisms of antibody resistance and methods to reduce resistance would be valuable in managing CLL. Monocyte derived cells (MDCs), also known as nurse like cells (NLCs) in CLL [1,2], are known to be crucial components of the CLL microenvironment network and following "maturation" in in vitro culture systems are able to provide support for the survival of the malignant B cells from CLL patients. In addition to their protective role, MDCs are key effector cells in mediating responses to therapeutic antibody therapies [3]. We have determined that macrophages from patients with early stable CLL are able to elicit superior cytotoxic response to therapeutic antibodies than macrophages derived from patients with progressive CLL. We have exploited this unique finding to gain insight into antibody resistance. Thus, we have profiled monocytes on day 0 and MDCs on day 7 from antibody sensitive and antibody resistant CLL patients (GEO accession number GEO: GSE71409). We show that there are no significant differences in transcriptomes from the monocytes or MDCs derived from sensitive or resistant patient samples. However, we show that MDCs acquire an M2-like macrophage transcriptomic signature following 7. days culture regardless of whether they were derived from sensitive or resistant patient samples.
Keyword Antibody resistance
Chronic lymphocytic leukemia
Microarray
Monocyte derived cells
Q-Index Code CX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
UQ Diamantina Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 08 Dec 2015, 00:13:08 EST by System User on behalf of Scholarly Communication and Digitisation Service